Home
News
默认头像

UniQure Says FDA Clears IND Application For AMT-191 Gene Therapy For Fabry Disease

2024-06-07MyfxbookMyfxbook
Gene therapy company uniQure N.V. (QURE) announced Wednesday that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-191, the Company's gene therapy candidate
UniQure Says FDA Clears IND Application For AMT-191 Gene Therapy For Fabry Disease

(RTTNews) - Gene therapy company uniQure N.V. (QURE) announced Wednesday that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-191, the Company's gene therapy candidate for Fabry disease.

AMT-191 is an AAV5 gene therapy product that delivers an a-galactosidase A (GLA) transgene designed to target the liver and produce the deficient GLA protein.

The company said it is looking forward to enrolling its first patient in the first half of 2024.

The first-in-human Phase I/IIa clinical trial will be conducted in the United States. The multicenter, open-label trial consists of two dose-escalating cohorts of three patients each to assess safety, tolerability, and efficacy of AMT-191 in patients with Fabry disease.

Disclaimers

The article is sourced from Myfxbook with the original source credited. The views expressed herein are not affiliated with FXOR; readers are encouraged to approach the content rationally. Copyright belongs to the original author. If unintentional infringement upon media or personal intellectual property rights has occurred, please contact us, and we will promptly remove the content. FXOR merely provides information storage services. The article is compiled and released by FXOR; reprints must indicate the original source.

Myfxbook Enter the brand column

Hottest

About 1 Year Ago

European stocks closed lower on Thursday on concerns the Federal Reserve might not reduce interest rates more than one time this year despite soft consumer price and producer price inflation data.

About 1 Year Ago

John Wiley & Sons, Inc. (WLY) reported Thursday net income for the first quarter of $25.27 million or $0.46 per share, sharply lower than $68.34 million or $1.22 per share in the prior-year quarter.

About 1 Year Ago

Asian stocks rose broadly on Thursday as soft U.S. inflation data helped keep the door open for a Federal Reserve rate cut in September.

About 1 Year Ago

While announcing its widely expected decision to leave interest rates unchanged on Wednesday, the Federal Reserve also revealed officials now expect only one interest rate cut this year. In support of its goals of

About 1 Year Ago

Asian stocks drifted lower on Wednesday as investors awaited key U.S. inflation data as well as a Federal Reserve policy decision later in the day for additional clues on the outlook for interest rates.

home

Home

home

Brokers

home

News

home

Expo

home

Mine